跳至主要内容
临床试验/PACTR201902478249291
PACTR201902478249291已完成2 期

Effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major

Beni suef university hospital0 个研究点目标入组 40 人开始时间: 2019年2月2日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

After 6 months, a significant reduction was noted in the MIC of patients receiving amlodipine (n=20), compared with the patients receiving the placebo (n=20). At baseline, the mean was 0.76±0.11 mg/g dry weight, while at 6 months, the mean was 0.51±0.07 mg/g dry weight (p< 0.001). Also, there was a significant change in the myocardial T2* after 6 months; the amlodipine increased the myocardial T2* from 40.63±5.45 ms at baseline to 43.25±5.35 ms (p< 0.001). However, amlodipine did not significantly affect the secondary outcomes by the end of the study.

研究设计

研究类型
Interventional

入排标准

年龄范围
6 Year(s) 至 12 Year(s)(—)
性别
All

入选标准

  • Patients eligible for enrollment at baseline were male or female aged between 6 and 18 years old with ß-Thalassemia major.
  • Potential participants had been diagnosed with thalassemia major (TM), as confirmed by the presence of microcytic hypochromic anemia and hemoglobin electrophoresis;
  • additionally, patients who had been receiving a regular blood transfusion during the last two years,
  • with a serum ferritin (SF) level more than 1000 ng /ml were also considered.

排除标准

  • Participants were excluded if they were more than 20 years old,
  • their SF was less than 1000 ng /ml,
  • they experienced heart failure (ejection fraction (EF) less than 30%),
  • they were contraindicated to undergo the magnetic resonance imaging (MRI) scan,
  • or they were expected to change their chelation therapy regimen during the next 6 months.

研究者

发起方
Beni suef university hospital

相似试验